SCHEMBL982532

SCHEMBL982532

CC[CH]OCCCCCCCCCCCCCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.42
TSHR P16473 1/20 0.42
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 1/20 0.39
CA1 P00915 8/20 0.38
CA2 P00918 8/20 0.38
CA9 Q16790 7/20 0.38
LPAR3 Q9UBY5 6/20 0.38
LPAR2 Q9HBW0 5/20 0.38
CA12 O43570 3/20 0.38
CA7 P43166 3/20 0.38
CA14 Q9ULX7 3/20 0.38
LPAR1 Q92633 2/20 0.38
CA3 P07451 2/20 0.38
CA4 P22748 2/20 0.38
CA6 P23280 2/20 0.38
CA5A P35218 2/20 0.38
CA5B Q9Y2D0 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL980210 1.00 THRB (0.42) THRBTSHRMEN1HTTKMT2A
SCHEMBL982824 1.00 THRB (0.42) THRBTSHRMEN1HTTKMT2A
SCHEMBL983250 1.00 THRB (0.42) THRBTSHRMEN1HTTKMT2A
SCHEMBL982044 1.00 THRB (0.42) THRBTSHRMEN1HTTKMT2A
SCHEMBL984576 1.00 THRB (0.42) THRBTSHRMEN1HTTKMT2A
SCHEMBL983446 1.00 THRB (0.42) THRBTSHRMEN1HTTKMT2A
SCHEMBL134426 1.00 THRB (0.42) THRBTSHRMEN1HTTKMT2A
SCHEMBL133829 1.00 THRB (0.42) THRBTSHRMEN1HTTKMT2A
SCHEMBL982845 1.00 THRB (0.42) THRBTSHRMEN1HTTKMT2A
SCHEMBL352666 1.00 THRB (0.42) THRBTSHRMEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4161596-A1 NANOFIBROUS MATERIAL PARTICULARLY FOR TOPICAL USE IN THERAPIES Univerzita Karlova (CZ) 2023-04-12 EP claimed
US-11135237-B2 Lipophosphonoxins of second generation, and their use USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2021-10-05 US claimed
US-20210220383-A1 LIPOPHOSPHONOXINS OF SECOND GENERATION, AND THEIR USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2021-07-22 US claimed
EP-3448865-B1 LIPOPHOSPHONOXINS OF SECOND GENERATION, AND THEIR USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) 2019-09-04 EP claimed
WO-2017186200-A1 LIPOPHOSPHONOXINS OF SECOND GENERATION, AND THEIR USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2017-11-02 WO claimed
EP-2527351-B1 Lipophosphonoxins, method of their preparation and use USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) 2013-12-11 EP claimed
CN-118302407-A Carbonyl compound, method for producing isocyanate compound, and isocyanate composition 旭化成株式会社 2024-07-05 CN disclosed
CN-118215651-A Method for producing isocyanate compound, method for producing urethane compound, method for recovering amine compound, and isocyanate composition 旭化成株式会社 2024-06-18 CN disclosed
WO-2023214017-A1 CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER VIROVET NV (BE) 2023-11-09 WO disclosed
WO-2023144163-A1 A GLUN2D INHIBITOR FOR USE IN THE TREATMENT OR RELAPSE PREVENTION OF A DEPRESSIVE EPISODE ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2023-08-03 WO disclosed
WO-2023080258-A1 CARBONYL COMPOUND, METHOD FOR PRODUCING CARBONYL COMPOUND, METHOD FOR PRODUCING ISOCYANATE COMPOUND, AND ISOCYANATE COMPOSITION 旭化成株式会社 2023-05-11 WO disclosed
WO-2023080257-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUNDS, METHOD FOR PRODUCING CARBAMATE COMPOUNDS, METHOD FOR RECOVERING AMINE COMPOUNDS, AND ISOCYANATE COMPOSITION 旭化成株式会社 2023-05-11 WO disclosed
EP-4161596-A1 NANOFIBROUS MATERIAL PARTICULARLY FOR TOPICAL USE IN THERAPIES Univerzita Karlova (CZ) 2023-04-12 EP disclosed
US-5412118-A Thickened foam stable compositions comprising alkyl(alkyl glycosid)uronamides LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) 1995-05-02 US disclosed
EP-0612777-A2 Thermosetting molding and expansion-forming compositions MITSUI TOATSU CHEMICALS, Inc. (JP) 1994-08-31 EP disclosed
EP-0612797-A2 Modification method of resins MITSUI TOATSU CHEMICALS, Inc. (JP) 1994-08-31 EP disclosed
WO-1994012511-A1 ALDONAMIDES AND THEIR USE AS SURFACTANTS UNILEVER PLC (GB) 1994-06-09 WO disclosed
EP-0313083-A2 Silver halide color photographic material FUJI PHOTO FILM CO., LTD. (JP) 1989-04-26 EP disclosed
EP-0301477-A2 Silver halide color photosensitive material and method of processing thereof Fuji Photo Film Co., Ltd. (JP) 1989-02-01 EP disclosed
EP-0059383-A1 Improver for the color fastness of dyed cotton textiles to chlorinated water and process for improving the color fastness of dyed cotton textiles to chlorinated water Dainippon Pharmaceutical Co., Ltd. (JP) 1982-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11135237-B2 Lipophosphonoxins of second generation, and their use PLA2G1B, PLA2G2E, PLA2G4C THRB 2528/4885TSHR 1768/4885MEN1 1905/4885
US-20210220383-A1 LIPOPHOSPHONOXINS OF SECOND GENERATION, AND THEIR USE PLA2G1B, PLA2G2E, PLA2G4C THRB 2528/4885TSHR 1768/4885MEN1 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.